GlassScriptPhysician profile
Alexis Pappas
NPI 1114161064
$3,807.96
in general payments reported to CMS, 2019-2025
24 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $133 · 2021: $71.72 · 2022: $422 · 2023: $1,275 · 2024: $903 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.31 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.98 | 2022-2025 | Xifaxan |
| Ardelyx, INC. | $497.91 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $299.03 | 2021-2025 | |
| Janssen Biotech, INC. | $183.82 | 2023-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $181.64 | 2023-2025 | |
| Pfizer INC. | $126.57 | 2023-2025 | |
| Sirtex Medical INC | $122.11 | 2019 | |
| Qol Medical, LLC | $113.62 | 2023-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $110.13 | 2021-2023 | |
| Conmed Corporation | $108.80 | 2020 | |
| Intuitive Surgical, INC. | $98.47 | 2023 | Da Vinci Surgical System |
| Celgene Corporation | $89.47 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $69.79 | 2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $62.00 | 2023-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $59.22 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $38.97 | 2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $32.07 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $30.56 | 2019-2023 | Dificid |
| Astrazeneca Pharmaceuticals LP | $24.23 | 2020 | |
| Lilly USA, LLC | $24.04 | 2024 | Omvoh |
| Lucid Diagnostics INC. | $24.01 | 2023 | |
| Ironwood Pharmaceuticals, INC | $22.04 | 2023 | Linzess |
| Shield Therapeutics INC | $18.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.